Evidence transferability

Can Ketone Ester Research Be Applied to R 1,3 Butanediol?

The two molecules share a metabolic pathway and both raise blood BHB, so the question gets asked a lot. The answer depends on which of five things is actually the same — and only one of them is.

The five-question test The chemistry, side by side

Short answer

No, not automatically. Research on the Veech Ketone Ester is direct evidence for the Veech Ketone Ester. Free R 1,3 butanediol has a related metabolic pathway but is a different administered molecule, with different pharmacokinetics and its own outcome evidence.

Both can raise blood BHB. VKE is not a mixture of D-BHB and free R 1,3 butanediol; it is one bonded ester molecule. After hydrolysis, VKE releases D-BHB directly and R 1,3 butanediol, which then follows the same hepatic conversion pathway described for free R 1,3 butanediol. That shared downstream step does not make the starting molecules, pharmacokinetics, dosing or trial evidence interchangeable. Identity comes first: a study describes the molecule it administered. Whether it then supports a specific claim depends on dose, protocol, population and the outcome measured — and those have to match too.

The test

Five things “the same” can mean. Only one holds.

When a butanediol product points at ketone-ester research, ask which of these it is claiming. Run down the list for the Veech Ketone Ester and free R 1,3 butanediol.

1Same downstream ketone body?Both end up as blood D-BHB.Yes — this is the one that holds
2Same molecule?One is a bonded ester of D-BHB and R 1,3 butanediol; the other is the free diol.No
3Same formulation?Free 1,3-butanediol can be administered as enantiopure R material or as racemic R,S material. Those are different study materials; neither is the intact Veech Ketone Ester.No
4Same dose and protocol?At a matched 10 g, the ester produced roughly twice the BHB rise. Equal grams are not equal exposure.No — not even at matched dose
5Same outcome evidence?The ester’s human trials dosed the ester. The free diol’s trials dosed the diol.No — each has its own

A shared ketone body at the end of the pathway is real. It is also the only link that holds — and a biomarker in common is not evidence in common. The result belongs to the molecule that was tested.

The identity-first framework

The fair question

Does VKE release R 1,3 butanediol? Yes — after hydrolysis.

VKE itself is one intact bonded molecule. After hydrolysis, it releases one D-BHB molecule directly and one R 1,3 butanediol molecule; the released diol then follows the same hepatic conversion pathway described for free R 1,3 butanediol.

So a butanediol-derived conversion step is part of how the ester delivers ketones. Here is why that does not make a free R 1,3 butanediol product equivalent to the intact ester, or let it inherit the ester’s trial results.

The trials administered intact VKE. The human VKE evidence tested the bonded ester molecule, not free R 1,3 butanediol as the administered ingredient. The evidence attaches to what was given.
Hydrolysis releases D-BHB directly. One product of ester hydrolysis is already D-BHB and requires no hepatic conversion to become D-BHB.
The released R 1,3 butanediol then requires hepatic conversion. That is the shared metabolic step with free R 1,3 butanediol. In the one study that gave both molecules to the same people at the same 10 g, the ester still produced roughly twice the BHB rise — same grams, different curve.
A shared downstream step does not merge the evidence bases. A trial of intact VKE is still a trial of intact VKE; a trial of free R 1,3 butanediol is still needed to support an outcome claim for the free diol.

The two routes are drawn step by step on the metabolism page; this page does not repeat them.

What was actually administered in the ester trials

Intact VKE → hydrolysis → D-BHB + R 1,3 butanediol

Shared downstream metabolism ≠ same administered molecule ≠ same pharmacokinetics ≠ same outcome evidence.

Study by study

What the ester research is — and is not — evidence for.

Four kinds of Veech Ketone Ester study, read through the identity-then-applicability framework. In each row, the first question is which molecule was administered.

The study	Direct evidence for	For free R 1,3 butanediol
Human kinetics of the esterClarke 2012 · Stubbs 2017	How much BHB the intact ester delivers, how fast, and for how long — 2.8 mM at 12–24 g, a 3.30 mM peak at 714 mg/kg, back to baseline in 3–4 h.	Does not transfer. The free diol has its own kinetics: about 1.2 mM peak from 10 g, about 2.1 mM from 34.5 g in three fasted servings, with a later peak.Falkenhain 2024 · Lowder 2023
Both molecules, same people, same doseFalkenhain 2024	The one head-to-head: at a matched 10 g in twelve fasted adults, the ester rose about +1.7 mM above baseline, free R 1,3 butanediol about +0.8 mM.*	This is evidence about the free diol — because it dosed the free diol. It shows the biomarker itself does not carry over at equal grams.
Repeated-use ester trial with a measured outcomePoffé 2019	Physically active young men, 25 g of the ester after exercise and before sleep for three weeks of overload: sustainable training load and late-endurance power about 15% higher than control.	Does not transfer. Identity fails at link 2. There is no free-diol trial of this protocol, and a kinetics study cannot stand in for one.
Acute ester trials with a measured outcome — positive, unchanged and negativeMcCarthy 2023 · Poffé 2021 · Prins 2026	What the ester did under those doses and protocols, including two short time trials where power was 1.5–2.4% lower.	Does not transfer — in either direction. The ester’s negative results are not the diol’s either. A molecule inherits neither the wins nor the losses of another.

* Approximate rise above baseline calculated from the published baseline and peak values, not treatment-effect figures quoted verbatim from the paper. A twelve-person pharmacokinetic pilot; it measured BHB exposure, not performance or cognition.

Ester research is direct evidence for

The Veech Ketone Ester, under the protocols tested

Positive, unchanged and negative results alike — all of them describe the intact molecule that was administered.

It is not evidence for

A different administered molecule

Free R 1,3 butanediol shares a pathway and a ketone body. It does not share the trials.

Every indexed VKE study

The bar

What would substantiate an outcome claim for free R 1,3 butanediol?

The same thing that substantiates one for any molecule. Nothing about the shared pathway lowers the bar or raises it.

1A controlled human trial that administered free R 1,3 butanediol.With the isomer stated in the Methods. Racemic (R,S) material is a different formulation, and a study that only says “1,3-butanediol” has not established which was given.Identity — links 1 to 3

2At a dose and timing comparable to the product’s use.Because equal grams are not equal exposure across molecules, the diol’s own dose–response has to be established, not borrowed.Applicability — link 4

3Measuring the outcome being claimed.Performance, cognition, recovery — measured directly, against a comparator, with the result reported whichever way it went. A BHB curve is exposure, not an outcome.Applicability — link 5

4Published, and read in full.Primary versus secondary endpoints, funding, tolerability, correspondence. The ten checks apply to a diol study exactly as they apply to an ester study.Method — how to read a study

The free-diol examples on this page

Human outcome evidence on free 1,3-butanediol has to be evaluated on its own formulation and protocol.

The examples on this page are one racemic R,S-1,3-butanediol cycling trial and one endurance trial whose abstract does not state the administered isomer; neither showed an endurance-performance benefit. Two human kinetics studies describe how (R)-1,3-butanediol raises BHB. These examples are not presented as a complete review of every free-diol outcome paper. They are enough to demonstrate the evidence-transfer rule: an ester trial cannot substitute for a free-diol trial, and a free-diol trial cannot substitute for an ester trial.

Consumer takeaway

Follow the molecule that was actually tested.

1Find the chemical name in the study.Not “ketone ester,” not “ketones,” not “BHB.” The compound the Methods say was given.

2Match it to the label.If the label says R 1,3 butanediol and the study gave (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, the citation is about a different product.

3Then check dose, protocol and outcome.Even on the right molecule, a result belongs to its protocol and its measured outcome — not to every use of the ingredient.

4Expect the whole record.Any molecule’s evidence includes its neutral and negative trials. The ester’s does. Ask to see the diol’s.

Same ketone body downstream. Different molecule in the bottle. The research follows the second, not the first.

Compare products by molecule Ke4 — the Veech Ketone Ester

From evidence to the bottle

Want the molecule from the VKE study? Start with VKE.

KetoneAid products contain Veech Ketone Ester. Free R 1,3 Butanediol can raise BHB and has its own research, but it does not inherit VKE outcomes — and VKE does not inherit its outcomes either.

The simplest buying rule is the same as the evidence rule: identify the molecule first, then decide whether the protocol and outcome fit what you want to do.

Shop KetoneAid Compare products by molecule

50% VKEKe4Most concentrated · best-sellingShop Ke4 →

25% VKEKe2More diluted · balance of taste and valueShop Ke2 →

8% VKEKetone ShotReady to drink · easiest way to try VKEShop Ketone Shot →

Go deeper

The chemistry, the framework, the record.

The chemistry

Back to Ketone Science

References cited on this page

Clarke K, Tchabanenko K, Pawlosky R, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012;63(3):401–408. PubMed ↗Also the source for the statement that the released R 1,3 butanediol portion is converted in the liver by alcohol and aldehyde dehydrogenase.
Stubbs BJ, Cox PJ, Evans RD, et al. On the Metabolism of Exogenous Ketones in Humans. Front Physiol. 2017;8:848. PubMed ↗ · Study index
Falkenhain K, Daraei A, Little JP. The Effect of Novel Exogenous Ketone Supplements on Blood Beta-Hydroxybutyrate and Glucose. J Diet Suppl. 2024;21(1):38–52. PubMed ↗Matched 10 g crossover, 12 fasted adults; rise-above-baseline figures are calculations from the published values. The (R)-1,3-butanediol peak (1.2 ± 0.3 mM at ~40 min) is as reported by Lowder et al. 2023.
Lowder J, Fallah S, Venditti C, Musa-Veloso K, Kotlov V. An open-label, acute clinical trial in adults to assess ketone levels, gastrointestinal tolerability, and sleepiness following consumption of (R)-1,3-butanediol. Front Physiol. 2023;14:1195702. PubMed ↗Open-label, uncontrolled, one-group acute study, n = 26; manufacturer-funded with the funder involved in design. Kinetics and tolerability only.
Poffé C, Ramaekers M, Van Thienen R, Hespel P. Ketone ester supplementation blunts overreaching symptoms during endurance training overload. J Physiol. 2019;597(12):3009–3027. PubMed ↗ · Study index
McCarthy DG, Bone J, Fong M, et al. Acute Ketone Monoester Supplementation Impairs 20-min Time-Trial Performance in Trained Cyclists: A Randomized, Crossover Trial. Int J Sport Nutr Exerc Metab. 2023;33(4):181–188. PubMed ↗ · Study index
Poffé C, Wyns F, Ramaekers M, Hespel P. Exogenous Ketosis Impairs 30-min Time-Trial Performance Independent of Bicarbonate Supplementation. Med Sci Sports Exerc. 2021;53(5):1068–1078. PubMed ↗ · Study index
Prins PJ, Buga A, Storoschuk K, et al. The Effects of 31-Day Exogenous Ketone Consumption on Running Performance, Cognitive Function, Metabolism, Body Composition, Hemodynamics, and Mood in Recreational Runners: A Randomized-Control Trial. J Am Nutr Assoc. 2026;45(6):545–560. PubMed ↗ · Study index
Shaw DM, Merien F, Braakhuis A, Plews D, Laursen P, Dulson DK. The Effect of 1,3-Butanediol on Cycling Time-Trial Performance. Int J Sport Nutr Exerc Metab. 2019;29(5):466–473. PubMed ↗Racemic (R,S)-1,3-butanediol, 0.35 g/kg twice; 9 trained male cyclists; no time-trial benefit.
Carpenter M, Brouner J, Spendiff O. Acute 1,3-Butanediol Co-Ingestion with Carbohydrate Does Not Improve Endurance Performance in Chronically Ketogenic Male Athletes. Nutrients. 2026. PubMed ↗0.5 g/kg 1,3-butanediol with 60 g carbohydrate; n = 9; 16.1-km time trial; the abstract does not state the isomer administered.